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Recently, there has been a movement in commercial biotechnology drug production to develop fully a 
continuous manufacturing scheme capable of consistent production of high quality therapeutics. The FDA is 
increasingly reviewing applications implementing elements of continuous manufacturing or enabling 
technologies. This includes product and process engineering, and integration of enabling technology during 
development. Achieving a true continuous process can be difficult and raise additional unknown regulatory 
concerns (i.e. how to handle process interruptions or unmatched liquid flow rates between linked unit 
operations, how to measure viral clearance and establish safety). This poster will provide an overview of 
CDER’s, Office of Biotechnology Product’s lab capabilities and selected regulatory research case studies on 
continuous biomanufacturing and enabling technologies.  These lab-based capabilities are being leveraged to 
study continuous bioreactor cell culture production, continuous chromatography, viral safety, and Process 
Analytical Technology (PAT) tools to enable these operations. Preliminary results have provided encouraging 
data to broaden technological challenges and potential benefits of continuous biomanufacturing approaches.  
 
